NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE was delisted on the 10th of May, 2024.
33 hedge funds and large institutions have $1.05M invested in NeuBase Therapeutics, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 3 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
6% less funds holding
Funds holding: 35 → 33 (-2)
8% less capital invested
Capital invested by funds: $1.13M → $1.05M (-$88K)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
71% less call options, than puts
Call options by funds: $4K | Put options by funds: $14K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$36.6K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$34.3K |
| 3 |
VF
Virtu Financial
New York
|
+$6.37K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$5.24K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$2.79K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Leisure Capital Management
Costa Mesa,
California
|
-$14K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$7.77K |
| 3 |
GBA
Garrison Bradford & Associates
New York
|
-$6.81K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$6.02K |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
JP Morgan Chase
New York
| $1K | – | – | – |
|
27
Morgan Stanley
New York
| $1K | +$436 | +5 | +56% |
|
|
LCM
28
Leisure Capital Management
Costa Mesa,
California
| – | -$14K | -161 | Closed |
|
|
29
Balyasny Asset Management
Chicago,
Illinois
| – | -$5K | -61 | Closed |
|
30
Simplex Trading
Chicago,
Illinois
| – | -$1.05K | -12 | Closed |
|
|
SSA
31
Schonfeld Strategic Advisors
New York
| – | +$2.79K | +32 | New |
|
NBSE Hedge Fund Activity: Q2 2018 in Review
33 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q2 2018, worth a combined $1.05M — down 7.8% from $1.13M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of NBSE and 1 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 6 added.
The largest buyer was Renaissance Technologies, adding an estimated $36.6K. The largest seller was Leisure Capital Management, exiting entirely with an estimated $14K sold.
- 33 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q2 2018, down from 35 in Q1 2018.
- Funds reported $1.05M of NeuBase Therapeutics, Inc. Common Stock stock for Q2 2018, down 7.8% quarter-over-quarter.
- 1 fund opened new NeuBase Therapeutics, Inc. Common Stock positions in Q2 2018 and 3 closed out, a net change of -2 holders.
- The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q2 2018 was Renaissance Technologies, an estimated $36.6K added.
- The largest NeuBase Therapeutics, Inc. Common Stock seller in Q2 2018 was Leisure Capital Management, an estimated $14K sold.
Based on aggregated 13F filings for Q2 2018.